AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12365904 — intervention group
Group type: COMPARATOR
Intervention: No initial treatment (n = 126)
Number of subjects: 255
Study 12365904 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty plus topical betaxolol hydrochloride
Number of subjects: 255
Study 9672331 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐s inflation duration (group A)
Number of subjects: 81
Study 9672331 — intervention group
Group type: COMPARATOR
Intervention: 6‐s inflation duration (group B)
Number of subjects: 81
Study 7978416 — intervention group
Group type: COMPARATOR
Intervention: ondansetron plus saline (Group 1)
Number of subjects: 180
Study 7978416 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron plus dexamethasone (Group 2)
Number of subjects: 180
Study 2726279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg + 20 mg codeine
Number of subjects: 25
Study 2726279 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 25
Study 820357 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic thyrotrophin releasing factor (TRF, Ro 08‐6270) administered via rapid i.v. injection
Number of subjects: 20
Study 820357 — intervention group
Group type: COMPARATOR
Intervention: Solvent only (placebo)
Number of subjects: 20
Study 31898636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichen Planus Severity Index (LPSI) used by 21 dermatologists scoring photographs of 4 patients.
Number of subjects: 27
Study 31898636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichen Planus Severity Index (LPSI) evaluated by 6 doctors on 10 real-world patients.
Number of subjects: 27
Study 31898636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichen Planus Severity Index (LPSI) compared with Physician Global Assessment score.
Number of subjects: 27
Study 30591415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 214
Study 30591415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 214
Study 30591415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab dose increase (from 75 to 150 mg Q2W)
Number of subjects: 214
Study 30591415 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 214
Study 29122148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) for 12 weeks
Number of subjects: 56
Study 29122148 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE) for 12 weeks
Number of subjects: 56
Study 26131612 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) program consisting of four 45‐minute sessions each week and daily walking for 30 minutes for 6 months
Number of subjects: 126
Study 26131612 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) program
Number of subjects: 126
Study 26131612 — intervention group
Group type: COMPARATOR
Intervention: Control group walking daily for 30 minutes
Number of subjects: 126
Study 23475405 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% (n = 56)
Number of subjects: 164
Study 23475405 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (n = 53)
Number of subjects: 164
Study 23475405 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% (n = 55)
Number of subjects: 164
Study 22071699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Glycemic Index (GI)
Number of subjects: 26
Study 22071699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Glycemic Load (GL)
Number of subjects: 26
Study 19361952 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5mg
Number of subjects: 333
Study 19361952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide 20mg
Number of subjects: 333
Study 19361952 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.25mg
Number of subjects: 333
Study 17725739 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous plasmapheresis
Number of subjects: 60
Study 17725739 — intervention group
Group type: COMPARATOR
Intervention: Control session (reclined position without plasma withdrawal)
Number of subjects: 60
Study 15207987 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention and an estimate of breast cancer risk over the telephone
Number of subjects: 392
Study 15207987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 392
Study 11405514 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg x day(-1))
Number of subjects: 24
Study 11405514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9514183 — intervention group
Group type: EXPERIMENTAL
Intervention: MO/HCTZ 3.75/6.25 mg once daily
Number of subjects: 223
Study 9514183 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 223
Study 9050476 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop electrosurgical conization
Number of subjects: 98
Study 9050476 — intervention group
Group type: COMPARATOR
Intervention: Cold knife conization
Number of subjects: 98
Study 3168445 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 236
Study 3168445 — intervention group
Group type: EXPERIMENTAL
Intervention: Amenorrheic cases
Number of subjects: 236
Study 30137242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine plus atazanavir/ritonavir
Number of subjects: 0
Study 30137242 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 0
Study 30137242 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor-based regimens
Number of subjects: 0
Study 30137242 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline I-FABP levels
Number of subjects: 0
Study 29251457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste plus 3.0% KNO3 mouthwash
Number of subjects: 135
Study 29251457 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste alone
Number of subjects: 135
Study 25494323 — intervention group
Group type: EXPERIMENTAL
Intervention: Superion interspinous process spacer
Number of subjects: 391
Study 25494323 — intervention group
Group type: COMPARATOR
Intervention: Control (X-Stop spacer)
Number of subjects: 391
Study 24116356 — intervention group
Group type: EXPERIMENTAL
Intervention: MCBA + 5.6 mL of rhBMP‐2/ACS (8.4 mg of rhBMP‐2)
Number of subjects: 18
Study 24116356 — intervention group
Group type: EXPERIMENTAL
Intervention: MCBA + 2.8 mL of rhBMP‐2/ACS (4.2 mg of rhBMP‐2)
Number of subjects: 18
Study 24116356 — intervention group
Group type: COMPARATOR
Intervention: MCBA only (control)
Number of subjects: 18
Study 21951654 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraarticular injection of 40 mg triamcinolone
Number of subjects: 60
Study 21951654 — intervention group
Group type: EXPERIMENTAL
Intervention: Two injections of 40 mg triamcinolone at 21‐day interval
Number of subjects: 60
Study 19469115 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with 10 mL of 0.5% bupivacaine before and at the end of surgery
Number of subjects: 60
Study 19469115 — intervention group
Group type: COMPARATOR
Intervention: Thoracic paravertebral analgesia (TPVA) with 30 mL of 0.5% bupivacaine before and 15 mL at the end of surgery
Number of subjects: 60
Study 17545082 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin solid lipid nanoparticle gel
Number of subjects: 97
Study 17545082 — intervention group
Group type: COMPARATOR
Intervention: Routine podophyllotoxin gel preparation
Number of subjects: 97
Study 12841414 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 84
Study 12841414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10699477 — intervention group
Group type: EXPERIMENTAL
Intervention: 33x2 Gy
Number of subjects: 155
Study 10699477 — intervention group
Group type: EXPERIMENTAL
Intervention: 8x5 Gy
Number of subjects: 155
Study 10699477 — intervention group
Group type: EXPERIMENTAL
Intervention: 4x7 Gy
Number of subjects: 155
Study 10699477 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation up to 66 Gy
Number of subjects: 155
Study 9373099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate indirect laser photocoagulation
Number of subjects: 19
Study 9373099 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 19
Study 8468105 — intervention group
Group type: EXPERIMENTAL
Intervention: Carleton Skill Training Program (CSTP) to increase hypnotic susceptibility
Number of subjects: 27
Study 8468105 — intervention group
Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 27
Study 8468105 — intervention group
Group type: EXPERIMENTAL
Intervention: Carleton Skill Training Program (CSTP)
Number of subjects: 27
Study 3514908 — intervention group
Group type: EXPERIMENTAL
Intervention: Butoconazole vaginal suppositories, 100 mg/day
Number of subjects: 185
Study 3514908 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole vaginal tablets, 200 mg/day
Number of subjects: 185
Study 3514908 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 185
Study 31996717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 161
Study 31996717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 161
Study 29581967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Muscle Strength Test (SMST) - Leg muscle strength
Number of subjects: 240
Study 29581967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Muscle Strength Test (SMST) - Back muscle strength
Number of subjects: 240
Study 29581967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Muscle Strength Test (SMST) - Sit-ups
Number of subjects: 240
Study 29581967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Muscle Strength Test (SMST) - Hand grip
Number of subjects: 240
Study 29581967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Muscle Strength Test (SMST) - Standing long jump
Number of subjects: 240
Study 29581967 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Muscle Strength Test (SMST) - Knee bent push-up
Number of subjects: 240
Study 27079965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27079965 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU
Number of subjects: 100
Study 27079965 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU
Number of subjects: 100
Study 24882205 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus DVD
Number of subjects: 40
Study 24882205 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 40
Study 24882205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Standard care and Standard care plus DVD)
Number of subjects: 40
Study 22422735 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 100
Study 22422735 — intervention group
Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 100
Study 20435293 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of dexketoprofen
Number of subjects: 111
Study 20435293 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL intrauterine 2% lidocaine
Number of subjects: 111
Study 20435293 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 111
Study 20435293 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 111
Study 19115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Alverine citrate plus simethicone (60 mg alverine citrate + 300 mg simethicone)
Number of subjects: 165
Study 19115153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 165
Study 19115153 — intervention group
Group type: EXPERIMENTAL
Intervention: Alverine citrate plus simethicone
Number of subjects: 165
Study 15861257 — intervention group
Group type: COMPARATOR
Intervention: Treadmill electrocardiographic stress testing (EST)
Number of subjects: 158
Study 15861257 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill echocardiographic stress testing (ExE)
Number of subjects: 158
Study 15861257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 158
Study 12364840 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT) for 12 weeks
Number of subjects: 32
Study 12364840 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group for 6 weeks
Number of subjects: 32
Study 12364840 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment of ABFT
Number of subjects: 32
Study 10472854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 0.025 mg/day
Number of subjects: 0
Study 10472854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 0.05 mg/day
Number of subjects: 0
Study 10472854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 0.06 mg/day
Number of subjects: 0
Study 10472854 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol 0.1 mg/day
Number of subjects: 0
Study 10472854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8752759 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of pure oxygen (O2) during EIS
Number of subjects: 50
Study 8752759 — intervention group
Group type: COMPARATOR
Intervention: No inhalation of pure oxygen (O2) during EIS
Number of subjects: 50
Study 1875807 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 60
Study 1875807 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid supplementation
Number of subjects: 60
Study 1875807 — intervention group
Group type: EXPERIMENTAL
Intervention: No supplementation
Number of subjects: 60
Study 1875807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no blood collection)
Number of subjects: 60
Study 6401230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.8 mg sublingually)
Number of subjects: 16
Study 6401230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (5 ng/kg/min i.v.)
Number of subjects: 16
Study 6401230 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (0.15 mg/kg i.v.)
Number of subjects: 16
Study 6401230 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 16
Study 31362561 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic alignment using patient-specific instrumentation (KA+PSI)
Number of subjects: 47
Study 31362561 — intervention group
Group type: COMPARATOR
Intervention: Mechanical alignment using computer-assisted surgery (MA+CAS)
Number of subjects: 47
Study 29088437 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLAS intervention training
Number of subjects: 13
Study 29088437 — intervention group
Group type: EXPERIMENTAL
Intervention: SOLAS intervention delivery
Number of subjects: 13
Study 26773321 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic complex (6cH each of Arnica montana, Bryonia alba, Causticum, Kalmia latifolia, Rhus toxicodendron, and Calcarea fluorica) plus standard physiotherapy (massage, thermal therapy, joint mobilization) every 2 weeks
Number of subjects: 30
Study 26773321 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard physiotherapy (massage, thermal therapy, joint mobilization) every 2 weeks
Number of subjects: 30
Study 24589127 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide plus insulin (LIRA)
Number of subjects: 37
Study 24589127 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin only (controls)
Number of subjects: 37
Study 22732458 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to three vegetables served at lunch on 10 separate occasions (30 days of exposure) in Preschool A.
Number of subjects: 96
Study 22732458 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer eating behaviors (greater consumption by tablemates).
Number of subjects: 96
Study 22732458 — intervention group
Group type: COMPARATOR
Intervention: Routine practice in Preschool B (control group).
Number of subjects: 96
Study 20858273 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Change Counselling (BCC) training for clinicians
Number of subjects: 2000
Study 20858273 — intervention group
Group type: COMPARATOR
Intervention: Non-BCC trained clinicians
Number of subjects: 2000
Study 17697104 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 62
Study 17697104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16286057 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled zanamivir 10 mg once daily for 14 days
Number of subjects: 494
Study 16286057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 12447551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Number of subjects: 12
Study 12447551 — intervention group
Group type: COMPARATOR
Intervention: Gastrectomy (Control)
Number of subjects: 12
Study 10087688 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent group CBT (16 two-hour sessions)
Number of subjects: 123
Study 10087688 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent group CBT with a separate parent group
Number of subjects: 123
Study 10087688 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments every 4 months with booster sessions
Number of subjects: 123
Study 10087688 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments only every 4 months
Number of subjects: 123
Study 10087688 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments only every 12 months
Number of subjects: 123
Study 10087688 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 123
Study 7491655 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 1 to 1.6 g intravenously
Number of subjects: 48
Study 1968731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (0.05 microgram/kg body weight/minute for 120 minutes) with placebo pretreatment
Number of subjects: 12
Study 1968731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion with atenolol pretreatment (beta-1-selective blocker)
Number of subjects: 12
Study 1968731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion with propranolol pretreatment (nonselective beta blocker)
Number of subjects: 12
Study 1968731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion with ICI 118551 pretreatment (beta-2-selective blocker)
Number of subjects: 12
Study 1968731 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion
Number of subjects: 12
Study 1968731 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion with different pretreatments
Number of subjects: 12
Study 387542 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, methotrexate, cyclophosphamide, and 5-fluorouracil (initiation course) followed by mitomycin-C with 5-fluorouracil (maintenance therapy)
Number of subjects: 76
Study 387542 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 30082892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 36 IU
Number of subjects: 47
Study 30082892 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 48 IU
Number of subjects: 47
Study 30082892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28109324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-CONSORT period
Number of subjects: 351
Study 28109324 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-CONSORT period
Number of subjects: 351
Study 26155878 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention technologies
Number of subjects: 0
Study 26155878 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 23143991 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 10
Study 23143991 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (12% O2; controlled gas mixture)
Number of subjects: 10
Study 22221684 — intervention group
Group type: EXPERIMENTAL
Intervention: IAADS (Improved Anesthetic Agent Delivery System)
Number of subjects: 40
Study 22221684 — intervention group
Group type: COMPARATOR
Intervention: Manual control (Tech 7 vaporizer)
Number of subjects: 40
Study 19419356 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular block
Number of subjects: 120
Study 19419356 — intervention group
Group type: COMPARATOR
Intervention: Supraclavicular block
Number of subjects: 120
Study 16426267 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 0
Study 16426267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster headache patients
Number of subjects: 0
Study 16426267 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study 15474248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C vaginal tablets (250 mg) once a day for 6 days
Number of subjects: 100
Study 15474248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15474248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C vaginal tablets
Number of subjects: 100
Study 14607676 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined transjugular intrahepatic portosystemic shunt (TIPS) and modified Sugiura
Number of subjects: 20
Study 14607676 — intervention group
Group type: COMPARATOR
Intervention: Modified Sugiura only
Number of subjects: 20
Study 14607676 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 20
Study 14607676 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sugiura (after TIPS in group A)
Number of subjects: 20
Study 9565942 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO drink
Number of subjects: 15
Study 9565942 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% CHO drink
Number of subjects: 15
Study 9565942 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 15
Study 9565942 — intervention group
Group type: EXPERIMENTAL
Intervention: Most liked fluid
Number of subjects: 15
Study 9565942 — intervention group
Group type: EXPERIMENTAL
Intervention: Least liked fluid
Number of subjects: 15
Study 7645388 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 27